Assembly Biosciences (ASMB) AI Stock Analysis

• Market Cap: $331.07M
• Dividend Yield: N/A
• Average Volume (3M): 64.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: 54.77%
• EPS Growth: 37.35%
• Country: US
• Employees: 73
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -1.33
• Shares Outstanding: 13,264,101
• 10 Day Avg. Volume: 142,738
• 30 Day Avg. Volume: 64,771
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.20
• Enterprise Value/Revenue: 2.82
• Enterprise Value/Gross Profit: 2.82
• Enterprise Value/Ebitda: -1.53
• 1Y Price Target: $28.33
• Price Target Upside: 11.36% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 58 Neutral
• Price Target: $25.00 ▼(-1.73% Downside)

The overall score is primarily impacted by financial distress, with no revenue and ongoing losses. However, strong technical momentum and positive corporate events provide some optimism for future growth.

Positive Factors

Drug Dosing

ABI-5366's PK profile is supportive of once-weekly or once-monthly dosing, which is highly encouraging.

Drug Safety and Dosing

ABI-5366 was safe and well-tolerated with up to 70 days of exposure with healthy volunteers in Phase 1a.

Drug Selectivity

ABI-6250 showed favorable selectivity for NTCP over other bile acid transporters in preclinical studies.

Oral Bioavailability

ABI-6250's oral bioavailability is a key attribute, indicating the potential for once-daily oral dosing, possibly becoming the first oral chronic HDV treatment.

Virology Readouts

Four 2025 Virology Readouts Provide Multiple Opportunities for Upside.

Negative Factors

Data Readout Delay

Data readout for ABI-5366, originally expected in the first half of 2025, has been delayed to Fall 2025.

Assembly Biosciences Business Overview & Revenue Model

Company Description

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

How the Company Makes Money

Assembly Biosciences generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies that seek to leverage its innovative research and development capabilities. The company may receive milestone payments, licensing fees, and royalties from these partnerships as its products advance through clinical trials and achieve regulatory approvals. Additionally, Assembly Biosciences may also generate revenue from grants or funding aimed at supporting its research initiatives and clinical development programs. The success of its drug candidates in clinical trials and subsequent commercialization will be crucial in determining its long-term revenue potential.

Assembly Biosciences Financial Statement Overview

Summary

Assembly Biosciences exhibits financial distress with no revenue in recent years, persistent net losses, and negative cash flows. Despite low leverage, declining equity and assets indicate potential financial instability.

Income Statement

Assembly Biosciences has faced significant challenges with consistent revenue declines from $79.1M in 2020 to $0 in 2022 and 2024, indicating potential instability. The company has struggled with persistent net losses and negative profit margins, including a net profit margin of -100% in 2024. These factors highlight major profitability issues.

Balance Sheet

While the company maintains a reasonable equity ratio of 28% in 2024, indicative of some financial stability, the declining stockholders' equity from $240.6M in 2020 to $33.4M in 2024 raises concerns. A relatively low debt-to-equity ratio of 0.09 in 2024 suggests manageable leverage, but the shrinking equity indicates potential risk.

Cash Flow

Assembly Biosciences experiences significant volatility in free cash flow, with figures dropping sharply from $22.5M in 2023 to -$51.1M in 2024. The negative operating cash flow and free cash flow pose risks to future liquidity and financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	23.62M	28.52M	7.16M	0.00	6.25M	79.11M
Gross Profit	23.59M	28.39M	-41.74M	-498.00K	5.79M	79.00M
EBITDA	-43.42M	-45.42M	-64.20M	-92.59M	-91.93M	-64.78M
Net Income	-38.96M	-40.18M	-61.23M	-92.07M	-129.85M	-59.53M
Balance Sheet
Total Assets	80.78M	119.17M	136.82M	101.79M	191.06M	283.25M
Cash, Cash Equivalents and Short-Term Investments	74.98M	112.08M	130.25M	91.61M	146.63M	216.41M
Total Debt	2.88M	3.09M	2.34M	3.46M	6.48M	10.13M
Total Liabilities	62.68M	85.81M	95.73M	19.13M	22.13M	42.68M
Stockholders Equity	18.10M	33.36M	41.10M	82.66M	168.93M	240.58M
Cash Flow
Free Cash Flow	-55.85M	-51.15M	22.49M	-84.56M	-96.49M	-65.18M
Operating Cash Flow	-55.85M	-51.12M	22.74M	-84.46M	-93.40M	-62.96M
Investing Cash Flow	41.37M	40.17M	-69.14M	90.64M	26.52M	68.07M
Financing Cash Flow	19.27M	29.45M	13.82M	614.00K	53.06M	7.60M

Assembly Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.44
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASMB, the sentiment is Positive. The current price of 25.44 is above the 20-day moving average (MA) of 20.50, above the 50-day MA of 18.80, and above the 200-day MA of 14.86, indicating a bullish trend. The MACD of 1.85 indicates Negative momentum. The RSI at 78.89 is Negative, neither overbought nor oversold. The STOCH value of 97.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASMB.

Assembly Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASMB	58 Neutral	$331.07M	―	-147.64%	―	54.77%	37.35%
Sector *	51 Neutral	$7.46B	-0.16	-46.00%	2.25%	22.76%	-2.28%
MNOV	―	$63.76M	―	-22.66%	―	―	―
VTYX	41 Neutral	$213.93M	―	-48.56%	―	―	39.76%
ABOS	36 Underperform	$84.80M	―	-75.71%	―	―	-103.31%
RANI	32 Underperform	$40.02M	―	-1372.59%	―	―	22.94%
GNTA	―	$63.28M	―	-54.30%	―	―	―

Assembly Biosciences Corporate Events

Assembly Biosciences Completes $175 Million Equity Financing

On August 8, 2025, Assembly Biosciences announced the pricing of a $175 million equity financing through an underwritten offering and a private placement. The offering, which closed on August 11, 2025, involved the sale of common stock and warrants, generating net proceeds of approximately $122 million. Additionally, Gilead Sciences participated in a private placement, contributing approximately $45 million. The funds raised will be used for general corporate purposes, potentially impacting Assembly Biosciences’ operations and market positioning by providing financial resources for ongoing and future projects.

The most recent analyst rating on (ASMB) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.

Assembly Biosciences Announces Positive Phase 1b Results

On August 8, 2025, Assembly Biosciences announced positive interim results from its Phase 1b clinical study of ABI-5366, a long-acting herpes simplex virus helicase-primase inhibitor candidate for recurrent genital herpes. The study showed a 94% reduction in HSV-2 shedding rate and genital lesion rate, and a 98% reduction in high viral load shedding rate compared to placebo, with the 350 mg weekly dose. The results exceeded the company’s targets and demonstrated a favorable safety profile, supporting the potential for once-weekly and once-monthly dosing regimens. These findings pave the way for Phase 2 clinical study preparations, with the company expecting to initiate these studies in mid-2026.

The most recent analyst rating on (ASMB) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.

Assembly Biosciences Reports Interim Results for ABI-6250

On August 6, 2025, Assembly Biosciences announced interim results from their Phase 1a clinical study of ABI-6250, a candidate for treating hepatitis delta virus (HDV). The company reported positive topline data from a Phase 1b study of ABI-4334 for chronic hepatitis B virus (HBV) and shared updates on their ongoing trials for herpes simplex virus (HSV) candidates ABI-5366 and ABI-1179. Financially, Assembly Biosciences reported a net loss of $10.2 million for the second quarter of 2025, with cash reserves projected to fund operations into mid-2026. The company continues to advance its clinical programs, aiming to deliver impactful datasets for its development candidates by the end of the year.

The most recent analyst rating on (ASMB) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.

Assembly Biosciences Reports Positive Phase 1b Trial Results

On June 25, 2025, Assembly Biosciences announced positive topline results from a Phase 1b clinical trial evaluating ABI-4334, a next-generation capsid assembly modulator, in participants with chronic hepatitis B virus infection. The trial demonstrated favorable safety, tolerability, and pharmacokinetics, supporting once-daily oral dosing. The results showed significant antiviral activity, with mean plasma HBV DNA reductions consistent across different dosage cohorts. These findings support the potential of ABI-4334 to inhibit viral replication and cccDNA formation, crucial for HBV treatment regimens. The completion of the trial triggers an opt-in point for collaboration with Gilead Sciences, Inc., which could impact future development and commercialization efforts.

The most recent analyst rating on (ASMB) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.

Assembly Biosciences Announces Stock Plan Amendments and Leadership Change

At the Annual Meeting of Stockholders on June 5, 2025, Assembly Biosciences, Inc. announced the approval of amendments to its 2018 Stock Incentive Plan and Employee Stock Purchase Plan, increasing the number of shares reserved for issuance. These amendments aim to enhance the company’s retention grant program and support employee stock purchases, reflecting a strategic move to bolster employee engagement and retention. Additionally, Jeanette M. Bjorkquist was appointed as the principal financial officer, succeeding Jason A. Okazaki, who remains the principal executive officer. This management change signifies a continued focus on strengthening the company’s financial leadership.

The most recent analyst rating on (ASMB) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.